Pulmonx Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LUNG in the last 30 days.
See all $LUNG insider activity →Pulmonx Corporation's average stock price target increased from $3.4 to $3.7, with estimates ranging from $2.5 to $5 per share, according to 5 analysts. This implies an 87% potential upside from the Oct. 27 closing price. The consensus rating remains 'Buy' with 3 Buys, 2 Holds, and 0 Sells.
Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.
Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Third Quarter 2026 Financial Results Redwood City, CA - October 27, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the thi
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning LUNG (Pulmonx Corp). Coverage has skewed bullish: 7 bullish, 4 neutral, and 0 bearish.
Recent LUNG coverage spans earnings, market movers and financial news.
Pulmonx Corporation's average stock price target increased from $3.4 to $3.7, with estimates ranging from $2.5 to $5 per share, according to 5 analysts. This implies an 87% potential upside from the Oct. 27 closing price. The consensus rating remains 'Buy' with 3 Buys, 2 Holds, and 0 Sells.
Earnings beat expectations and improved guidance suggest upside pressure.
Earnings beat on loss reduction and modest revenue growth.
The low revenue and negative EPS guidance suggest downward pressure on the stock.
The drop is likely short‑term and driven by technical sell‑off rather than new fundamentals.
AlphAI scores every news story that mentions LUNG with an AI model for sentiment and relevance, and aggregates insider trades from Pulmonx Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Pulmonx Corporation's average stock price target increased from $3.4 to $3.7, with estimates ranging from $2.5 to $5 per share, according to 5 analysts. This implies an 87% potential upside from the Oct. 27 closing price. The consensus rating remains 'Buy' with 3 Buys, 2 Holds, and 0 Sells.
1 min readPulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.
3 min readPulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Third Quarter 2026 Financial Results Redwood City, CA - October 27, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the thi
2 min readPulmonx (LUNG) to report Q3'26 earnings on October 27. Revenue estimated at $21.93M, EPS at -$0.26. Results to be released after market close.
1 min readPulmonx (LUNG) stock fell 10.1% in pre-market trading to $2.05, with no clear catalyst. The decline follows a recent rally from its 52-week low, and profit-taking is a possible reason. The company's Q2 2026 earnings showed a 5% revenue decline, and analysts remain cautious. Broader market weakness also contributed to the drop.
1 min readBiotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI
3 min readToday's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.
6 min readPulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.
4 min readPulmonx (Nasdaq: LUNG) reported Q2 2026 revenue of $22.8 million, down 5% year over year, with U.S. revenue at $14.2 million (-4%) and international at $8.6 million (-6%). Gross margin rose to 78%. Net loss was $10.1 million, down from $15.2 million. Full-year 2026 revenue guidance is $90 million to $92 million.
6 min readPulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the secon
3 min read
